In chronic myeloid leukemia (CML), hypermethylation of miR-203 has been shown to confer a growth advantage to tumor cells by downregulating the oncogenic BCR-ABL fusion protein [79,80]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.